Home » Umetrics Announces Global Sales Partnership with Sartorius Stedim Biotech
Umetrics Announces Global Sales Partnership with Sartorius Stedim Biotech
Under the cooperation agreement SSB will embed Umetrics technology into SSB products. SSB will assume global marketing and distribution of the Umetrics portfolio of Chemometrics software for the pharmaceutical and biopharmaceutical industries. SSB will also integrate Umetrics software programs as private label products into its own bioprocess portfolio and market these as stand-alone solutions under both brands under a dual branding arrangement.
The major areas of application for these software systems are critical process steps, such as cell culture processes or specific purification steps in the biopharmaceutical industry. Umetrics is a highly specialized, leading provider of chemometrics software worldwide for modeling and optimizing biopharmaceutical development and manufacturing processes. Multivariate data analysis (MVA) enables all process parameters to be added in batch trajectories, among other things, so that process variations and their causes can be displayed transparently in real time. DoE software (Design of Experiments) permits these critical process parameters to be efficiently identified and quantified and development cycles to be considerably shortened.
Lars Lindstrom GM of Umetrics said “Umetrics stands to benefit from the global sales structures of SSB. Thanks to SSB’s international reach and solid market standing in the biopharma sector, we can gain access to substantially more customers. SSB’s integrated solutions with embeded Umetrics MVA & DoE technology will clearly create added value for SSB and our customers. I anticipate that this will considerably boost the biopharmaceutical industry’s interest in and usage of Umetrics’ products”.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.” Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 2,850 people, and in 2011 earned sales revenue of 477.3 million euros.
Umetrics is a world leader in multivariate technology, providing software for design of experiments (DOE) and multivariate data analysis (MVDA). Umetrics offers complete solutions for both off-line and online data analysis (continuous and batch processes), all supported by training and consulting services. Umetrics is a subsidiary of MKS Instruments, Inc. (NASDAQ: MKSI), a worldwide provider of monitoring and control technologies. More information can be found at Umetrics web page.
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
- All news »